Helus Pharma Inc. (HELP)

NASDAQ Healthcare Medical - Pharmaceuticals

Helus Pharma Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $10.55, down 4.52% on the session, giving a market capitalisation of $653.9M. On trailing twelve-month figures it carries a trailing P/E of -2.54, a net margin of 0.0%. Its beta of 0.54 implies it has historically moved less than the broad market.

Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.